References of "Polus, Marc"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLe depistage generalise du cancer colorectal: une absolue necessite et une realite imminente en Communaute francaise.
Polus, Marc ULg; Montrieux, Christian ULg; Giet, Didier ULg et al

in Revue Médicale de Liège (2009), 64(2), 96-102

Colorectal cancer is a real problem of public health. Screening is an absolute necessity. An ambitious program of screening is launched in the French Community. Faecal occult blood test will be proposed ... [more ▼]

Colorectal cancer is a real problem of public health. Screening is an absolute necessity. An ambitious program of screening is launched in the French Community. Faecal occult blood test will be proposed to average risk patients in the general population. A total colonoscopy will be performed if FOBT is positive. First step colonoscopy will be proposed to high or very high risk patients. General practitioners are in the core of the multi-disciplinary program. [less ▲]

Detailed reference viewed: 80 (10 ULg)
Full Text
Peer Reviewed
See detailSurgical management of hepatic metastases of colorectal origin.
Gilson, Nathalie; Honore, Charles ULg; Detry, Olivier ULg et al

in Acta Gastro-Enterologica Belgica (2009), 72(3), 321-6

Colorectal cancer is the most frequent digestive cancer. Prognosis is greatly depending on the TNM stage at the time of diagnosis. Fifty percent of all patients shall develop, synchronously or ... [more ▼]

Colorectal cancer is the most frequent digestive cancer. Prognosis is greatly depending on the TNM stage at the time of diagnosis. Fifty percent of all patients shall develop, synchronously or metachronously, liver metastases. Different means such as chemotherapy, targeted therapies, radiofrequency ablation, portal vein embolization and two-stage hepatectomy may be used to make these metastases eventually resectable and to increase overall survival. This is a short review of these different methods used to increase resectability but also on the integration of these parameters in a larger approach of colorectal liver metastasis surgery especially insisting on multidisciplinary discussion. [less ▲]

Detailed reference viewed: 100 (6 ULg)
Full Text
Peer Reviewed
See detailQuand doit-on réséquer les métastases hépatiques d'un cancer colorectal?
Honoré, Charles ULg; Detry, Olivier ULg; Deroover, Arnaud ULg et al

in Revue Médicale de Liège (2008), 63(10), 595-599

6000 new cases of colorectal cancer are diagnosed each year in Belgium. 50% of these patients shall develop liver metastasis. Resection remains the only chance of long term survival and must be considered ... [more ▼]

6000 new cases of colorectal cancer are diagnosed each year in Belgium. 50% of these patients shall develop liver metastasis. Resection remains the only chance of long term survival and must be considered as an endpoint from the beginning of the treatment. It is the result of a multidisciplinary discussion and a global approach of the disease. It is rarely directly feasible, but there are many techniques which may make it achievable in the end. Today, resection criteria are exclusively technical and neitherbad prognosis factors, nor the presence of extra-hepatic metastases should exclude liver resection. This resecability must be assessed by a confirmed hepatobiliary surgeon and must be proposed to all patients whatever their age as long as their global status is good. [less ▲]

Detailed reference viewed: 129 (9 ULg)
Full Text
Peer Reviewed
See detailLe depistage du cancer colorectal
Piront, Patricia ULg; Louis, Edouard ULg; Belaiche, Jacques ULg et al

in Revue Médicale de Liège (2007), 62(1), 15-20

Colorectal cancer is the second leading cause of death in Northern countries and need a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and ... [more ▼]

Colorectal cancer is the second leading cause of death in Northern countries and need a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and acceptable for patients. Many screening tools, invasive or not, are existing and often debated: FOBT, sigmoidoscopy and complete colonoscopy. New tools are in development and have to be evaluated in current practice: virtual colonoscopy, new endoscopic technologies, DNA on faeces or proteomics with markers in serum. [less ▲]

Detailed reference viewed: 99 (2 ULg)
Full Text
Peer Reviewed
See detailScreening for colorectal cancer in 2006
Piront, Patricia ULg; Louis, Edouard ULg; Belaiche, Jacques ULg et al

in Acta Endoscopica (2007), 37(3), 305-313

Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and ... [more ▼]

Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and acceptable for patients. Many screening tools, invasive or not, are existing and often debated: FOBT, sigmoidoscopy and complete colonoscopy. New tools are in development and have to be evaluated in current practice: virtual colonoscopy, new endoscopic technologies, DNA on faeces or proteomics with markers in serum. [less ▲]

Detailed reference viewed: 20 (2 ULg)
Full Text
Peer Reviewed
See detailActualites therapeutiques en hepato-gastroenterologie
Belaiche, Jacques ULg; Delwaide, Jean ULg; Polus, Marc ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 303-9

During the last decade, advances in molecular biology and biotechnology allowed, the development of biological treatments aimed at more precise targets. New algorithms in inflammatory bowel diseases ... [more ▼]

During the last decade, advances in molecular biology and biotechnology allowed, the development of biological treatments aimed at more precise targets. New algorithms in inflammatory bowel diseases, chronic hepatitis C and digestive oncology are examples of the marked progress achieved by these therapies. [less ▲]

Detailed reference viewed: 91 (2 ULg)
Full Text
Peer Reviewed
See detailActualites en chirurgie et transplantation hepatique
Detry, Olivier ULg; De Roover, Arnaud ULg; Coimbra Marques, Carla ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 310-6

Over the last 20 years, significant improvements in hepatic surgery and transplantation have allowed better results. Better patients selection, new preoperative modalities aiming at modifying the volume ... [more ▼]

Over the last 20 years, significant improvements in hepatic surgery and transplantation have allowed better results. Better patients selection, new preoperative modalities aiming at modifying the volume of the liver or the tumour, new surgical techniques, and better postoperative management are the keys to improved outcome. These progresses are reviewed in this article. In hepatic surgery, the latest surgical improvements are the possibility of laparoscopic hepatic resection and of radiofrequency ablation. Modern neoadjuvant chemotherapy may in some cases allow a reduction of large liver colorectal metastases and render them resectable. Improved radiological techniques allow better planning of the surgical resections, reduction of the risks by calculation of the residual liver mass, and induction of liver hypertrophy by preoperative portal embolisation. In liver transplantation, the most significant changes were the use of living related liver donors and of non-heart beating donors to overcome the cadaveric organ donor shortage. [less ▲]

Detailed reference viewed: 159 (18 ULg)
Full Text
Peer Reviewed
See detailAdjuvant hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) Associated with curative surgery for locally advanced gastric carcinoma.An initial experience
De Roover, Arnaud ULg; Detroz, Bernard ULg; Detry, Olivier ULg et al

in Acta Chirurgica Belgica (2006), 106(3), 297-301

Aim of the study : After macroscopic radical (R0) surgery for advanced gastric carcinoma, 40 to 50% of the tumors recur in the abdomen as locoregional or peritoneal disease. We initiated a protocol in ... [more ▼]

Aim of the study : After macroscopic radical (R0) surgery for advanced gastric carcinoma, 40 to 50% of the tumors recur in the abdomen as locoregional or peritoneal disease. We initiated a protocol in which patients with suspicion of macroscopic serosal, lymphatic or peritoneal invasion, treated with R0 resection, underwent adjuvant HIPEC. Methods : Between June 1998 and January 2003, 16 patients with locally advanced adenocarcinoma of the stomach were included in the study. Surgery consisted of a total gastrectomy with a D2 lymphadenectomy. Splenectomy (n = 1), splenopancreatectomy (n = 4), transverse colectomy (n = 3), left hepatectomy (n = 1), localized peritonectomy (n = 3) were associated to obtain a R0 resection. HIPEC protocol consisted of heated (42.5°C) intraperitoneal mitomycin C (15 mg/m2) for a planned duration of 90 minutes. Results : HIPEC median duration was limited to 73(20-90) min because of central hyperthermia recognition in half of the cases. One patient died in the postoperative period of sepsis secondary to a duodenal fistula. Postoperative morbidity included pancreatic fistula (n = 2), pulmonary oedema (n = 1), pulmonary embolus (n = 1) and transient renal failure (n = 1). UICC staging was IB (n = 2), II (n = 2), IIIA (n = 5), IIIB (n = 1), IV (n = 6). Nine of the 16 patients are alive without recurrence with a median follow-up of 52 months. Four patients developed a recurrence, intraperitoneal (n = 2), systemic (n = 1), or combined (n = 1). Two patients were lost to follow-up. Conclusions : Aggressive surgical therapy and HIPEC might represent the standard of care in a selected population with locoregional disease and for whom a R0 resection can be achieved. This protocol was associated in this study with a 75% 5-year survival with a low peritoneal recurrence rate and an acceptable morbidity. [less ▲]

Detailed reference viewed: 179 (7 ULg)
Full Text
Peer Reviewed
See detailCarcinoid tumor of the appendix: A consecutive series from 1237 appendectomies
Tchana-Sato, Vincent ULg; Detry, Olivier ULg; Polus, Marc ULg et al

in World Journal of Gastroenterology (2006), 12(41), 6699-6701

AIM: To report the experience of the CHU Sart Tilman, University of Liege, Belgium, in the management of appendiceal carinoid tumor. METHODS: A retrospective review of 1237 appendectomies performed in one ... [more ▼]

AIM: To report the experience of the CHU Sart Tilman, University of Liege, Belgium, in the management of appendiceal carinoid tumor. METHODS: A retrospective review of 1237 appendectomies performed in one single centre from January 2000 to May 2004, was undertaken. Analysis of demographic data, clinical presentation, histopathology, operative reports and outcome was presented. RESULTS: Among the 1237 appendectomies, 5 appendiceal carcinoid tumors were identified (0.4%) in 4 male and 1 female patients, with a mean age of 29.2 years (range: 6-82 years). Acute appendicitis was the clinical presentation for all patients. Four patients underwent open appendectomy and one a laparoscopic procedure. One patient was reoperated to complete the excision of mesoappendix. All tumors were located at the tip of the appendix with a mean diameter of 0.6 cm (range: 0.3-1.0 cm). No adjuvant therapy was performed. All patients were alive and disease-free during a mean follow-up of 33 mo. CONCLUSION: Appendiceal carcinoid tumor most often presents as appendicitis. In most cases, it is found incidentally during appendectomies and its diagnosis is rarely suspected before histological examination. Appendiceal carcinoid tumor can be managed by simple appendectomy and resection of the mesoappendix, if its size is <= 1 cm. (C) 2006 The WJG Press. All rights reserved. [less ▲]

Detailed reference viewed: 225 (14 ULg)
Full Text
Peer Reviewed
See detailClinicopathologic analysis of appendiceal tumors from 1,237 apendectomies
Tchanasato, V.; Laurent, S.; Thiry, Albert ULg et al

in Acta Gastro-Enterologica Belgica (2005, January), 68(1), 08

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailTraitement du cancer du sein chez la personne âgée
Gillain, Sophie ULg; Gennigens, Christine ULg; Sautois, Brieuc ULg et al

in Revue Médicale Suisse (2004), 62

Le cancer du sein représente chez la personne âgée une pathologie fréquente. Le choix du traitement dépend de l'âge physiologique, des pathologies et comorbidités associées ainsi que du niveau de vie et d ... [more ▼]

Le cancer du sein représente chez la personne âgée une pathologie fréquente. Le choix du traitement dépend de l'âge physiologique, des pathologies et comorbidités associées ainsi que du niveau de vie et d'autonomie. De plus, selon les facteurs histopronostiques (récepteurs aux oestrogènes et à la progestérone, la surexpression du cerb-B2) on décidera éventuellement du schéma thérapeutique le plus approprié. Chez la personne âgée, la chirurgie (mastectomie ou tumorectomie), la radiothérapie et l'hormonothérapie trouvent leur place. Au-delà de 70 ans, la place de la chimiothérapie est incertaine. En effet, les patientes de plus de 70 ans sont sous-représentées dans les études randomisées. [less ▲]

Detailed reference viewed: 245 (5 ULg)
Full Text
Peer Reviewed
See detailLiver resection for noncolorectal, nonneuroendocrine metastases
Detry, Olivier ULg; Warzee, Fabian ULg; Polus, Marc ULg et al

in Acta Chirurgica Belgica (2003), 103(5), 458-462

In noncolorectal, nonendocrine liver metastases, the role of surgery is less define than in colorectal or neuroendocrine cancer. This role is marginal as liver is not the primary site of metastases of ... [more ▼]

In noncolorectal, nonendocrine liver metastases, the role of surgery is less define than in colorectal or neuroendocrine cancer. This role is marginal as liver is not the primary site of metastases of these cancers. Less than 2 to 5% of the patients with these malignancies might be one day considered as potential candidates for liver resection, as most patients suffer from extra hepatic tumour spread at the time they develop liver involvement. However, in these few cases with liver metastases only, as no other therapeutic option may provide mid- or long-term tumour-free survival, liver resection is indicated in resectable liver metastases. Some prognostic factors have been established in the literature from the few published series : unique versus multiple hepatic metastases, unilobar vs bilobar, metachronous vs synchronous, R0 vs R1 or R2 liver resections. The type of primary tumour is also of great importance, as cutaneous melanoma, pancreatic and gastric adenocarcinoma have a very bad prognosis for liver resection of metastases, even after R0 resection. In these cases, percutaneous or laparoscopic radiofrequency ablation may find its place. In sarcoma, breast carcinoma, uveal melanoma, and genitourinary cancers, liver resection may provide satisfactory long-term results in selected cases, and is the standard of care for isolated, resectable metastasis. However, due to the scarcity of indication of liver resection for noncolorectal, nonneuroendocrine metastases, the decision should be multidisciplinary, and the patients should be informed of the advantages and pitfalls of the surgical procedure. [less ▲]

Detailed reference viewed: 44 (6 ULg)
Full Text
Peer Reviewed
See detailPrevention primaire et secondaire du cancer colorectal
Polus, Marc ULg; Piront, Patricia ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2003), 58(4), 247-53

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed ... [more ▼]

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed, particularly by aspirin and non steroidal anti-inflammatory drugs. Development of specific cyclooxygenase-2 inhibitors constitutes a promising research's field. Secondary prevention by coloscopy and polypectomy must lead to a lower rate of colorectal cancer disease and improvement of mortality. [less ▲]

Detailed reference viewed: 120 (2 ULg)
Full Text
Peer Reviewed
See detailLa carcinomatose hepatique du cancer colorectal: actualites therapeutiques
Polus, Marc ULg; Honore, Pierre ULg; De Roover, Arnaud ULg et al

in Revue Médicale de Liège (2002), 57(12), 771-8

Important progress has been made in the treatment of liver metastases of advanced colorectal cancer. Surgery with curative intent, when possible, shows evidence of prolonged survival. Response rate and ... [more ▼]

Important progress has been made in the treatment of liver metastases of advanced colorectal cancer. Surgery with curative intent, when possible, shows evidence of prolonged survival. Response rate and overall survival can be improved with modern polychemotherapy. Cytotoxic drug combinations and sequential treatments sometimes make surgery possible for initially non resectable lesions. Impact of loco-regional treatment such as hepatic arterial infusion chemotherapy must be defined in randomised trials. Radiofrequency ablation is also currently evaluated in clinical trials. In this review the benefit of each treatment is discussed. [less ▲]

Detailed reference viewed: 215 (6 ULg)
Full Text
Peer Reviewed
See detailComment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene
Pelerin, D.; Silvestre, R. M.; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2002), 57(12), 755-6

Thromboembolic complications are well known side effects of treatment with tamoxifen in patients with breast cancer. The authors review the pathophysiology and the risk factors that increase the ... [more ▼]

Thromboembolic complications are well known side effects of treatment with tamoxifen in patients with breast cancer. The authors review the pathophysiology and the risk factors that increase the probability to develop these complications. The most appropriate treatment is discussed. [less ▲]

Detailed reference viewed: 41 (0 ULg)
Full Text
Peer Reviewed
See detailImplications pathologiques du systeme neuroendocrinien digestif
Piette, Caroline ULg; Polus, Marc ULg; Louis, Edouard ULg

in Revue Médicale de Liège (2002), 57(8), 509-18

The neuroendocrine system is made of endocrine cells disseminated in various organs. In this article, we will focus on the implication of the neuroendocrine system in digestive pathology. First of all, we ... [more ▼]

The neuroendocrine system is made of endocrine cells disseminated in various organs. In this article, we will focus on the implication of the neuroendocrine system in digestive pathology. First of all, we will review the neuroendocrine tumors in every location and then describe their classification, epidemiology, symptomatology, diagnosis and treatment. Finally, we will consider the implications of the neuroendocrine system in the inflammatory and functional pathology of the digestive tract. [less ▲]

Detailed reference viewed: 46 (5 ULg)
Full Text
Peer Reviewed
See detailComment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles
Polus, Marc ULg; Bours, Vincent ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2002), 57(7), 428-32

A better knowledge of fundamental mechanisms of carcinogenesis allows the development of novel therapeutic tools specifically targeting the cancer cell. Our understanding of cellular and molecular ... [more ▼]

A better knowledge of fundamental mechanisms of carcinogenesis allows the development of novel therapeutic tools specifically targeting the cancer cell. Our understanding of cellular and molecular mechanisms controlling cellular cycle and cell survival is an important step for new anti-cancer treatments. This review will focus on new therapeutic's strategies in advanced pancreatic cancer. [less ▲]

Detailed reference viewed: 64 (3 ULg)
Full Text
Peer Reviewed
See detailComment je traite.... Un cancer du pancreas avance
Polus, Marc ULg; Jerusalem, Guy ULg; Sautois, Brieuc ULg et al

in Revue Médicale de Liège (2002), 57(3), 131-4

Median survival of advanced pancreatic cancer is about three months. Unfortunately, chemotherapy is not a curative approach. Chemotherapy improves the quality of life and overall survival compared to best ... [more ▼]

Median survival of advanced pancreatic cancer is about three months. Unfortunately, chemotherapy is not a curative approach. Chemotherapy improves the quality of life and overall survival compared to best supportive care. Nevertheless, as the overall survival remains disappointing, clinical research must ongoing to define better treatment regimen. [less ▲]

Detailed reference viewed: 76 (2 ULg)
Full Text
Peer Reviewed
See detailEtude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection a visee curative du cancer du pancreas: resultats de l'etude randomisee ESPAC-1
Polus, Marc ULg; Jerusalem, Guy ULg; Sautois, Brieuc ULg et al

in Revue Médicale de Liège (2002), 57(2), 119-22

The prognosis of pancreatic adenocarcinoma remains poor, with a 5-year survival rate lower than 5%. Resection, the gold standard treatment, can be performed in less than 15% of patients. Following surgery ... [more ▼]

The prognosis of pancreatic adenocarcinoma remains poor, with a 5-year survival rate lower than 5%. Resection, the gold standard treatment, can be performed in less than 15% of patients. Following surgery, the median survival is 12 months for the most favourable cancer patients. Adjuvant treatment have attempted to improve results. However, chemotherapy, radiotherapy and multimodal treatments don't have demonstrated a clear advantage in controlled trials. We will discuss results of the current trials in this topic. The randomised trial of the European Study Group for Pancreatic Cancer (ESPAC) recently published in the Lancet revealed a potential benefit of adjuvant chemotherapy. A critical analysis of the publication showed, however, that definitive conclusions of this trial must be interpreted with caution. [less ▲]

Detailed reference viewed: 42 (2 ULg)